GlassScriptPhysician profile
Elizabeth Bishop
NPI 1013150663
$14,154.00
in general payments reported to CMS, 2019-2025
36 companies · $4,272 in 2025
The $4,272 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,453 · 2022: $2,229 · 2023: $2,726 · 2024: $2,475 · 2025: $4,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,272 · Consulting Fee: $1,050 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,272.38 |
| Consulting Fee | $1,050.00 |
| Education | $149.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,224.21 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,293.47 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $2,166.64 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $853.52 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $678.84 | 2022-2025 | |
| Celgene Corporation | $560.57 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $485.01 | 2024-2025 | Zenpep, Vowst |
| Pfizer INC. | $477.12 | 2021-2025 | |
| Daiichi Sankyo INC. | $398.79 | 2021-2023 | Injectafer |
| Celltrion USA INC. | $396.82 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Gilead Sciences, INC. | $304.89 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $283.97 | 2023-2025 | Dupixent |
| Redhill Biopharma INC. | $281.26 | 2022-2024 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $218.30 | 2021-2023 | |
| Qol Medical, LLC | $218.25 | 2022-2025 | Sucraid |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.